Skip to main content
. 2015 Mar 4;10(3):e0118672. doi: 10.1371/journal.pone.0118672

Fig 3. Prognosis analysis based on signature D123, P125, PN12567 in independent validation set.

Fig 3

A-B, predictive performance of D123 according to both LOOCV and HC. C-D, P125 successfully divided patients into two significant groups by LOOCV (p = 0.012) but not by hierarchical clustering. E-F, PN12567 performed well in LOOCV (p = 0.035) and patients classified by HC also showed different OS rates but not significant (p = 0.075).